Oxcarbazepine (All indications)

Intrauterine deaths (as a whole or unspecified)

id	Study   Auto Trivedi (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018Trivedi (Oxcarbazepine) (Controls unexposed, sick), 2018Vajda (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018Vajda (Oxcarbazepine) (Controls unexposed, sick), 2018Tomson (Oxcarbazepine), 2015	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S9078 R31076	Trivedi (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018	Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation)	1st trimester	prospective cohort	exposed to other treatment, sick excluded	Adjustment: No	1.08 [0.27;4.27] C excluded (control group)	5/56   4/48	9	56		ref
S9079 R31077	Trivedi (Oxcarbazepine) (Controls unexposed, sick), 2018	Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation)	1st trimester	prospective cohort	unexposed, sick	Adjustment: Yes	7.53 [1.54;36.89]	5/56   5/178	10	56		ref
S9080 R31078	Vajda (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018	Intrauterine foetal death	throughout pregnancy	prospective cohort	exposed to other treatment, sick excluded	Adjustment: No	1.46 [0.18;11.73] C excluded (control group)	1/19   14/382	15	19		ref
S9081 R31079	Vajda (Oxcarbazepine) (Controls unexposed, sick), 2018	Intrauterine foetal death	throughout pregnancy	prospective cohort	unexposed, sick	Adjustment: No	8.94 [0.53;137.30]	1/19   1/170	2	19		ref
S9077 R31074	Tomson (Oxcarbazepine), 2015	Intrauterine death	at least 1st trimester	prospective cohort	exposed to other treatment, sick	Adjustment: No	1.08 [0.67;1.72] C	22/262   150/1,910	172	262		ref
					Total	3 studies	3.13 [0.62;15.80]		184	337
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded 9078, 9080